{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:02:09Z","timestamp":1740142929334,"version":"3.37.3"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4701 and F4704"],"award-info":[{"award-number":["F4701 and F4704"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Austrian Science Fund (FWF)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00508-018-1355-7","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T06:33:28Z","timestamp":1531463608000},"page":"517-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10\u00a0years and future perspectives"],"prefix":"10.1007","volume":"130","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emir","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Grunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Karlic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schulenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Hubmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medhat","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Selzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"R\u00fclicke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Marian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pfeilst\u00f6cker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Pehamberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Keil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105\u201311.","journal-title":"Nature"},{"key":"1355_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nrc1232","volume":"3","author":"R Pardal","year":"2003","unstructured":"Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895\u2013902.","journal-title":"Nat Rev Cancer"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nm1379","volume":"12","author":"K Polyak","year":"2006","unstructured":"Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12:296\u2013300.","journal-title":"Nat Med"},{"key":"1355_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/107327480401100216","volume":"11","author":"ML Guzman","year":"2004","unstructured":"Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control. 2004;11:97\u2013104.","journal-title":"Cancer Control"},{"issue":"S2","key":"1355_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.0960-135X.2004.01368.x","volume":"34","author":"WR Sperr","year":"2004","unstructured":"Sperr WR, Hauswirth AW, Florian S, Ohler L, Geissler K, Valent P. Human leukaemic stem cells: a\u00a0novel target of therapy. Eur J Clin Invest. 2004;34(S2):31\u201340.","journal-title":"Eur J Clin Invest"},{"key":"1355_CR6","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983\u20138.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/cncr.22277","volume":"107","author":"A Schulenburg","year":"2006","unstructured":"Schulenburg A, Ulrich-Pur H, Thurnher D, Erovic B, Florian S, Sperr WR, et al. Neoplastic stem cells: a\u00a0novel therapeutic target in clinical oncology. Cancer. 2006;107:2512\u201320.","journal-title":"Cancer"},{"key":"1355_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"1355_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a\u00a0hierarchy that originates from a\u00a0primitive hematopoietic cell. Nat Med. 1997;3:730\u20137.","journal-title":"Nat Med"},{"key":"1355_CR10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ni1080","volume":"5","author":"KJ Hope","year":"2004","unstructured":"Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a\u00a0hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738\u201343.","journal-title":"Nat Immunol"},{"key":"1355_CR11","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","volume":"26","author":"E Kavalerchik","year":"2008","unstructured":"Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J\u00a0Clin Oncol. 2008;26:2911\u20135.","journal-title":"J Clin Oncol"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11899-009-0010-9","volume":"4","author":"M Copland","year":"2009","unstructured":"Copland M. Chronic myelogenous leukemia stem cells: What\u2019s new? Curr Hematol Malig Rep. 2009;4:66\u201373.","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"1355_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2010.159","volume":"24","author":"I Sloma","year":"2010","unstructured":"Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010;24(11):1823\u201333.","journal-title":"Leukemia"},{"key":"1355_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111\u20135.","journal-title":"Nature"},{"key":"1355_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106\u201310.","journal-title":"Nature"},{"key":"1355_CR16","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et\u00a0al. Identification of a\u00a0cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821\u20138.","journal-title":"Cancer Res"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1073\/pnas.0610117104","volume":"104","author":"ME Prince","year":"2007","unstructured":"Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et\u00a0al. Identification of a\u00a0subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973\u20138.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1355_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature06489","volume":"451","author":"T Schatton","year":"2008","unstructured":"Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature. 2008;451:345\u20139.","journal-title":"Nature"},{"key":"1355_CR19","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1200\/JCO.2007.15.5465","volume":"26","author":"SE Zabierowski","year":"2008","unstructured":"Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J\u00a0Clin Oncol. 2008;26:2890\u20134.","journal-title":"J Clin Oncol"},{"key":"1355_CR20","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2007.15.8428","volume":"26","author":"CA Huff","year":"2008","unstructured":"Huff CA, Matsui W. Multiple myeloma cancer stem cells. J\u00a0Clin Oncol. 2008;26:2895\u2013900.","journal-title":"J Clin Oncol"},{"key":"1355_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nature07567","volume":"456","author":"E Quintana","year":"2008","unstructured":"Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593\u20138.","journal-title":"Nature"},{"issue":"2","key":"1355_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.critrevonc.2010.01.001","volume":"76","author":"A Schulenburg","year":"2010","unstructured":"Schulenburg A, Br\u00e4mswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C, Pehamberger H, Grunt T, J\u00e4ger U, Zielinski CC, Valent P. Neoplastic stem cells: current concepts and clinical perspectives. Crit Rev Oncol Hematol. 2010;76(2):79\u201398.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1355_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/456581a","volume":"456","author":"CJ Eaves","year":"2008","unstructured":"Eaves CJ. Cancer stem cells: here, there, everywhere? Nature. 2008;456:581\u20132.","journal-title":"Nature"},{"key":"1355_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.10.012","volume":"18","author":"E Quintana","year":"2010","unstructured":"Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et\u00a0al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010;18:510\u201323.","journal-title":"Cancer Cell"},{"key":"1355_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/blood-2007-10-118331","volume":"112","author":"DC Taussig","year":"2008","unstructured":"Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112:568\u201375.","journal-title":"Blood"},{"key":"1355_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","volume":"141","author":"A Roesch","year":"2010","unstructured":"Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583\u201394.","journal-title":"Cell"},{"key":"1355_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N\u00a0Engl J Med. 2004;351:657\u201367.","journal-title":"N Engl J Med"},{"key":"1355_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","volume":"19","author":"N Goardon","year":"2011","unstructured":"Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19:138\u201352.","journal-title":"Cancer Cell"},{"key":"1355_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gde.2003.11.007","volume":"14","author":"M Al-Hajj","year":"2004","unstructured":"Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:43\u20137.","journal-title":"Curr Opin Genet Dev"},{"key":"1355_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ncponc1110","volume":"5","author":"A Trumpp","year":"2008","unstructured":"Trumpp A, Wiestler OD. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol. 2008;5:337\u201347.","journal-title":"Nat Clin Pract Oncol"},{"key":"1355_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11899-010-0043-0","volume":"5","author":"GV Helgason","year":"2010","unstructured":"Helgason GV, Young GA, Holyoake TL. Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep. 2010;5:81\u20137.","journal-title":"Curr Hematol Malig Rep"},{"key":"1355_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2174\/156800911793743655","volume":"11","author":"P Valent","year":"2011","unstructured":"Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011;11:56\u201371.","journal-title":"Curr Cancer Drug Targets"},{"key":"1355_CR33","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.2174\/138161212799859701","volume":"18","author":"JA McCubrey","year":"2012","unstructured":"McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, et\u00a0al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr Pharm Des. 2012;18:1784\u201395.","journal-title":"Curr Pharm Des"},{"key":"1355_CR34","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.4161\/cc.5.24.3573","volume":"5","author":"DJ Barnes","year":"2006","unstructured":"Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle. 2006;5:2862\u20136.","journal-title":"Cell Cycle"},{"key":"1355_CR35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21:926\u201335.","journal-title":"Leukemia"},{"key":"1355_CR36","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741\u201351.","journal-title":"Oncogene"},{"key":"1355_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2010.31.0904","volume":"29","author":"MY Konopleva","year":"2011","unstructured":"Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J\u00a0Clin Oncol. 2011;29:591\u20139.","journal-title":"J Clin Oncol"},{"key":"1355_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-015-0113-9","volume":"8","author":"A Schulenburg","year":"2015","unstructured":"Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B, Grunt TW, Zielinski CC, Valent P. Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J\u00a0Hematol Oncol. 2015;8:16.","journal-title":"J Hematol Oncol"},{"key":"1355_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","volume":"13","author":"HS Zhou","year":"2016","unstructured":"Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: yin and yang. Cancer Biol Med. 2016;13:248\u201359.","journal-title":"Cancer Biol Med"},{"issue":"12","key":"1355_CR40","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129(12):1595\u2013606.","journal-title":"Blood"},{"key":"1355_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2010.03.002","volume":"20","author":"M Greaves","year":"2010","unstructured":"Greaves M. Cancer stem cells: back to Darwin? Semin Cancer Biol. 2010;20:65\u201370.","journal-title":"Semin Cancer Biol"},{"key":"1355_CR42","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1084\/jem.20110105","volume":"208","author":"E Clappier","year":"2011","unstructured":"Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L, et\u00a0al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J\u00a0Exp Med. 2011;208:653\u201361.","journal-title":"J Exp Med"},{"key":"1355_CR43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrc3368","volume":"12","author":"P Valent","year":"2012","unstructured":"Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et\u00a0al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767\u201375.","journal-title":"Nat Rev Cancer"},{"key":"1355_CR44","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3324\/haematol.2011.054734","volume":"97","author":"SJ Horton","year":"2012","unstructured":"Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. Haematologica. 2012;97:966\u201374.","journal-title":"Haematologica"},{"key":"1355_CR45","doi-asserted-by":"publisher","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","volume":"4","author":"M Jan","year":"2012","unstructured":"Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra118.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1355_CR46","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-12-3678","volume":"73","author":"P Valent","year":"2013","unstructured":"Valent P, Bonnet D, W\u00f6hrer S, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res. 2013;73(3):1037\u201345.","journal-title":"Cancer Res"},{"key":"1355_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ng1941","volume":"39","author":"M Widschwendter","year":"2007","unstructured":"Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39:157\u20138.","journal-title":"Nat Genet"},{"key":"1355_CR48","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nature08989","volume":"464","author":"L Ding","year":"2010","unstructured":"Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a\u00a0basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999\u20131005.","journal-title":"Nature"},{"key":"1355_CR49","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","volume":"366","author":"MJ Walter","year":"2012","unstructured":"Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et\u00a0al. Clonal architecture of secondary acute myeloid leukemia. N\u00a0Engl J Med. 2012;366:1090\u20138.","journal-title":"N Engl J Med"},{"key":"1355_CR50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506\u201310.","journal-title":"Nature"},{"key":"1355_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/path.2220","volume":"213","author":"A Schulenburg","year":"2007","unstructured":"Schulenburg A, Cech P, Herbacek I, Marian B, Wrba F, Valent P, et al. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J\u00a0Pathol. 2007;213:152\u201360.","journal-title":"J Pathol"},{"key":"1355_CR52","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00508-010-1408-z","volume":"122","author":"H Karlic","year":"2010","unstructured":"Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, et\u00a0al. Tumor stem cell research\u2014basis and challenge for diagnosis and therapy. Wien Klin Wochenschr. 2010;122:423\u201336.","journal-title":"Wien Klin Wochenschr"},{"key":"1355_CR53","first-page":"560","volume":"5","author":"TW Grunt","year":"2015","unstructured":"Grunt TW, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, et al. Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. Am J Cancer Res. 2015;5:560\u201374.","journal-title":"Am J Cancer Res"},{"key":"1355_CR54","doi-asserted-by":"publisher","first-page":"e84417","DOI":"10.1371\/journal.pone.0084417","volume":"9","author":"I Mirkina","year":"2014","unstructured":"Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, et al. Phenotyping of human melanoma cells reveals a\u00a0unique composition of receptor targets and a\u00a0subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS ONE. 2014;9:e84417.","journal-title":"PLoS ONE"},{"key":"1355_CR55","doi-asserted-by":"publisher","first-page":"65627","DOI":"10.18632\/oncotarget.11593","volume":"7","author":"K Blatt","year":"2016","unstructured":"Blatt K, Herrmann H, Stefanzl G, Sperr WR, Valent P. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. Oncotarget. 2016;7:65627\u201342.","journal-title":"Oncotarget"},{"key":"1355_CR56","first-page":"577","volume":"7","author":"P Valent","year":"2013","unstructured":"Valent P, Grunt T, Karlic H, Herrmann H, Marian B, Schulenburg A, et\u00a0al. The Vienna Cancer Stem Cell Club (VCSCC): first 10 years and future perspectives. J\u00a0Life Sci. 2013;7:577\u201385.","journal-title":"J Life Sci"},{"key":"1355_CR57","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","volume":"31","author":"P Valent","year":"2007","unstructured":"Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et\u00a0al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a\u00a0working conference. Leuk Res. 2007;31:727\u201336.","journal-title":"Leuk Res"},{"key":"1355_CR58","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","volume":"30","author":"J Schanz","year":"2012","unstructured":"Schanz J, T\u00fcchler H, Sol\u00e9 F, Mallo M, Lu\u00f1o E, Cervera J, et\u00a0al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J\u00a0Clin Oncol. 2012;30:820\u20139.","journal-title":"J Clin Oncol"},{"key":"1355_CR59","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1355_CR60","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","volume":"128","author":"M Pfeilst\u00f6cker","year":"2016","unstructured":"Pfeilst\u00f6cker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sol\u00e9 F, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128:902\u201310.","journal-title":"Blood"},{"key":"1355_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9\u201316.","journal-title":"Blood"},{"key":"1355_CR62","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/asheducation-2015.1.299","volume":"2015","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Cazzola M. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology Am Soc Hematol Educ Program. 2015;2015:299\u2013307.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1355_CR63","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N\u00a0Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"1355_CR64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2017-07-746453","volume":"131","author":"LI Shlush","year":"2018","unstructured":"Shlush LI. Age-related clonal hematopoiesis. Blood. 2018;131:496\u2013504.","journal-title":"Blood"},{"key":"1355_CR65","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","volume":"35","author":"CJ Gibson","year":"2017","unstructured":"Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J\u00a0Clin Oncol. 2017;35:1598\u2013605.","journal-title":"J Clin Oncol"},{"key":"1355_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a\u00a0case-control study. Lancet Oncol. 2017;18:100\u201311.","journal-title":"Lancet Oncol"},{"key":"1355_CR67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/leu.2017.200","volume":"32","author":"VI Gaidzik","year":"2018","unstructured":"Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, et al. German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018;32:30\u20137.","journal-title":"Leukemia"},{"key":"1355_CR68","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N\u00a0Engl J Med. 2018;378:1189\u201399.","journal-title":"N Engl J Med"},{"key":"1355_CR69","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a\u00a0primary target site. Leukemia. 2017;31:2388\u201397.","journal-title":"Leukemia"},{"key":"1355_CR70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et\u00a0al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N\u00a0Engl J Med. 2017;377:111\u201321.","journal-title":"N Engl J Med"},{"key":"1355_CR71","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3324\/haematol.2010.035006","volume":"97","author":"H Herrmann","year":"2012","unstructured":"Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, et al. CD34(+)\/CD38(\u2212) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin. Haematologica. 2012;97:219\u201326.","journal-title":"Haematologica"},{"key":"1355_CR72","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","volume":"123","author":"H Herrmann","year":"2014","unstructured":"Herrmann H, Sadovnik I, Cerny-Reiterer S, R\u00fclicke T, Stefanzl G, Willmann M, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123:3951\u201362.","journal-title":"Blood"},{"key":"1355_CR73","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/eci.12368","volume":"44","author":"P Valent","year":"2014","unstructured":"Valent P, Sadovnik I, R\u00e1\u010dil Z, Herrmann H, Blatt K, Cerny-Reiterer S, et al. DPPIV (CD26) as a\u00a0novel stem cell marker in Ph+ chronic myeloid leukaemia. Eur J Clin Invest. 2014;44:1239\u201345.","journal-title":"Eur J Clin Invest"},{"key":"1355_CR74","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-15-0767","volume":"22","author":"I Sadovnik","year":"2016","unstructured":"Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, et al. Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML. Clin Cancer Res. 2016;22:2051\u201361.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1355_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/156800912798888992","volume":"12","author":"H Herrmann","year":"2012","unstructured":"Herrmann H, Kneidinger M, Cerny-Reiterer S, R\u00fclicke T, Willmann M, Gleixner KV, et al. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on CD34+\/CD38+ and CD34+\/CD38\u2212 AML progenitor cells. Curr Cancer Drug Targets. 2012;12(1):51\u201363.","journal-title":"Curr Cancer Drug Targets"},{"issue":"12","key":"1355_CR76","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.18632\/oncotarget.733","volume":"3","author":"H Herrmann","year":"2012","unstructured":"Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, M\u00fcllauer L, et al. Small-molecule inhibition of BRD4 as a\u00a0new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget. 2012;3(12):1588\u201399.","journal-title":"Oncotarget"},{"key":"1355_CR77","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-13-2811","volume":"20","author":"K Blatt","year":"2014","unstructured":"Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, et al. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML. Clin Cancer Res. 2014;20:3589\u2013602.","journal-title":"Clin Cancer Res"},{"key":"1355_CR78","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1182\/blood-2009-10-248054","volume":"116","author":"M Shehata","year":"2010","unstructured":"Shehata M, Hubmann R, Hilgarth M, Schnabl S, Demirtas D, Ponath E, et\u00a0al. Partial characterization and in vitro expansion of putative CLL precursor\/stem cells which are dependent on bone marrow microenvironment for survival. Blood. 2010;116:2433.","journal-title":"Blood"},{"key":"1355_CR79","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V124.21.817.817","volume":"124","author":"G Eisenwort","year":"2014","unstructured":"Eisenwort G, Peter B, Blatt K, Cerny-Reiterer S, Hoermann G, Sadovnik I, et al. Identification of a\u00a0neoplastic stem cell in human mast cell leukemia. Blood. 2014;124:817.","journal-title":"Blood"},{"key":"1355_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.04.004","author":"K Blatt","year":"2018","unstructured":"Blatt K, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Eisenwort G, Rabitsch W, et al. Phenotypic characterization and target expression profiles in CD34+\/CD38\u2212 and CD34+\/CD38+ stem- and progenitor cells in acute lymphoblastic leukemia (ALL). Neoplasia. 2018; https:\/\/doi.org\/10.1016\/j.neo.2018.04.004 .","journal-title":"Neoplasia"},{"key":"1355_CR81","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.critrevonc.2010.05.008","volume":"78","author":"J Loeffler-Ragg","year":"2011","unstructured":"Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, et al. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2011;78:150\u201361.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1355_CR82","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","volume":"18","author":"SJ Hogg","year":"2017","unstructured":"Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18:2162\u201374.","journal-title":"Cell Rep"},{"key":"1355_CR83","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, B\u00f6hm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752\u20139.","journal-title":"Blood"},{"key":"1355_CR84","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","volume":"39","author":"MT Krauth","year":"2009","unstructured":"Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E\u2011dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39:1711\u201320.","journal-title":"Clin Exp Allergy"},{"key":"1355_CR85","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2015.242","volume":"30","author":"B Peter","year":"2016","unstructured":"Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, et\u00a0al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30:464\u201372.","journal-title":"Leukemia"},{"key":"1355_CR86","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of Midostaurin in advanced systemic mastocytosis. N\u00a0Engl J Med. 2016;374:2530\u201341.","journal-title":"N Engl J Med"},{"key":"1355_CR87","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","volume":"28","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, et\u00a0al. Midostaurin: a\u00a0magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017;28:2367\u201376.","journal-title":"Ann Oncol"},{"key":"1355_CR88","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10428190500272507","volume":"47","author":"S Florian","year":"2006","unstructured":"Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, et al. Detection of molecular targets on the surface of CD34+\/CD38\u2212-stem cells in various myeloid malignancies. Leuk Lymphoma. 2006;47:207\u201322.","journal-title":"Leuk Lymphoma"},{"key":"1355_CR89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2362.2007.01746.x","volume":"37","author":"AW Hauswirth","year":"2007","unstructured":"Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, et\u00a0al. Expression of the target receptor CD33 in CD34+\/CD38\u2212\/CD123+ AML stem cells. Eur J Clin Invest. 2007;37:73\u201382.","journal-title":"Eur J Clin Invest"},{"key":"1355_CR90","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00277-014-2218-6","volume":"94","author":"J Loke","year":"2015","unstructured":"Loke J, Khan JN, Wilson JS, Craddock C, Wheatley K. Mylotarg has potent anti-leukaemic effect: a\u00a0systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol. 2015;94:361\u201373.","journal-title":"Ann Hematol"},{"key":"1355_CR91","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","volume":"130","author":"FR Appelbaum","year":"2017","unstructured":"Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130:2373\u20136.","journal-title":"Blood"},{"key":"1355_CR92","doi-asserted-by":"publisher","first-page":"E567","DOI":"10.1002\/ajh.24847","volume":"92","author":"WR Sperr","year":"2017","unstructured":"Sperr WR, Herndlhofer S, Gleixner K, Girschikofsky M, Weltermann A, Machherndl-Spandl S, et al. Intensive consolidation with G\u2011CSF support: tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients \u226560 years. Am J Hematol. 2017;92:E567\u2013E74.","journal-title":"Am J Hematol"},{"issue":"12 Pt 1","key":"1355_CR93","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-04-0185","volume":"10","author":"WR Sperr","year":"2004","unstructured":"Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, et al. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1\u202fg\/m2 on days 1, 3, and 5). Clin Cancer Res. 2004;10(12 Pt 1):3965\u201371.","journal-title":"Clin Cancer Res"},{"key":"1355_CR94","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.4049\/jimmunol.176.3.1759","volume":"176","author":"MT Krauth","year":"2006","unstructured":"Krauth MT, Florian S, B\u00f6hm A, Sonneck K, Agis H, Samorapoompichit P, et al. Immunological characterization and antibacterial function of persisting granulocytes in leukemic patients receiving pulse cytosine arabinoside-consolidation chemotherapy on days 1, 3, and 5. J\u00a0Immunol. 2006;176:1759\u201368.","journal-title":"J Immunol"},{"key":"1355_CR95","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000443526","volume":"8","author":"P Valent","year":"2016","unstructured":"Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, et al. Paul Ehrlich (1854\u20131915) and his contributions to the foundation and birth of translational medicine. J\u00a0Innate Immun. 2016;8:111\u201320.","journal-title":"J Innate Immun"},{"key":"1355_CR96","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ebiom.2017.11.024","volume":"26","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, et al. Proposed terminology and classification of pre-malignant neoplastic conditions: a consensus proposal. EBioMedicine. 2017;26:17\u201324.","journal-title":"EBioMedicine"},{"issue":"4","key":"1355_CR97","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2017.15","volume":"31","author":"P Valent","year":"2017","unstructured":"Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, et\u00a0al. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia. 2017;31(4):788\u201397.","journal-title":"Leukemia"},{"key":"1355_CR98","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","volume":"8","author":"P Valent","year":"2017","unstructured":"Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8:73483\u2013500.","journal-title":"Oncotarget"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-018-1355-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T21:14:36Z","timestamp":1604610876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-018-1355-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":98,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s00508-018-1355-7","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2018,7,13]]},"assertion":[{"value":"14 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Valent, E.\u00a0Hadzijusufovic, T.\u00a0Grunt, H.\u00a0Karlic, B.\u00a0Peter, H.\u00a0Herrmann, G.\u00a0Eisenwort, G.\u00a0Hoermann, A.\u00a0Schulenburg, M.\u00a0Willmann, R.\u00a0Hubmann, M.\u00a0Shehata, E.\u00a0Selzer, K.V.\u00a0Gleixner, T.\u00a0R\u00fclicke, W.R.\u00a0Sperr, B.\u00a0Marian, M.\u00a0Pfeilst\u00f6cker, H.\u00a0Pehamberger, F.\u00a0Keil, U.\u00a0J\u00e4ger and C.\u00a0Zielinski declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}